CRSP Sep 2024 57.500 put
- Zacks
Is Most-Watched Stock CRISPR Therapeutics AG (CRSP) Worth Betting on Now?
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- Zacks
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note
CRISPR Therapeutics AG (CRSP) reachead $59.60 at the closing of the latest trading day, reflecting a -1.6% change compared to its last close.
- Globe Newswire
CRISPR Therapies Market Research 2024: Pipeline Analysis, Therapeutic Assessment, Unmet Needs, Impact of Drugs
Dublin, June 14, 2024 (GLOBE NEWSWIRE) -- The "CRISPR therapies - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This "CRISPR Therapies - Pipeline Insight, 2024," report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in CRISPR Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of admini
